QUOTIENT

What this means for you

Not registered yet, but its 20 Nov 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98278615

Mark type

Stylized text

Filed

20 Nov 2023

Attorney of record

Christina M. Licursi

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases

Owner

• Quotient Therapeutics, Inc., Cambridge, MA, US

Prosecution history

• 02 Feb 2026 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 27 Jul 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 21 Jan 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 21 Mar 2024 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 21 Mar 2024 — LETTER OF SUSPENSION E-MAILED
• 21 Mar 2024 — SUSPENSION LETTER WRITTEN
• 19 Mar 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 19 Mar 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 19 Mar 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 26 Feb 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 26 Feb 2024 — NON-FINAL ACTION E-MAILED
• 26 Feb 2024 — NON-FINAL ACTION WRITTEN
• 20 Feb 2024 — ASSIGNED TO EXAMINER
• 03 Jan 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 23 Nov 2023 — NEW APPLICATION ENTERED